These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 32972719)
21. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome. Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852 [TBL] [Abstract][Full Text] [Related]
23. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958 [TBL] [Abstract][Full Text] [Related]
24. Curative-Intent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck in Sri Lanka: The Impact of Radiotherapy Technique on Survival. Rupasinghe T; Silva DC; Balawardena J; Perera K; Gunasekera D; Weerasinghe S; Jeyakumaran N; Abeysinghe P; Skandarajah T; Choudhury A; Joseph N Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):765-772. PubMed ID: 34642066 [TBL] [Abstract][Full Text] [Related]
25. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. Oksuz DC; Prestwich RJ; Carey B; Wilson S; Senocak MS; Choudhury A; Dyker K; Coyle C; Sen M Radiat Oncol; 2011 May; 6():54. PubMed ID: 21609453 [TBL] [Abstract][Full Text] [Related]
26. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor. Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682 [TBL] [Abstract][Full Text] [Related]
27. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242 [TBL] [Abstract][Full Text] [Related]
28. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168 [TBL] [Abstract][Full Text] [Related]
29. Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. Nayak S; Bhatt MLB; Goel MM; Gupta S; Mahdi AA; Mishra A; Mehrotra D PLoS One; 2018; 13(6):e0199665. PubMed ID: 29953521 [TBL] [Abstract][Full Text] [Related]
30. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284 [TBL] [Abstract][Full Text] [Related]
31. Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. Elbers JBW; Al-Mamgani A; van den Brekel MWM; Jóźwiak K; de Boer JP; Lohuis PJFM; Willems SM; Verheij M; Zuur CL Otolaryngol Head Neck Surg; 2019 Jun; 160(6):1023-1033. PubMed ID: 30526317 [TBL] [Abstract][Full Text] [Related]
32. Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Howard J; Masterson L; Dwivedi RC; Riffat F; Benson R; Jefferies S; Jani P; Tysome JR; Nutting C Cochrane Database Syst Rev; 2016 Dec; 12(12):CD010963. PubMed ID: 27943254 [TBL] [Abstract][Full Text] [Related]
33. Oncological results of salvage laryngectomy in patients with laryngeal carcinoma. León X; Montoro V; Rovira C; Neumann E; López M; García J; Quer M Acta Otorrinolaringol Esp (Engl Ed); 2020; 71(2):70-77. PubMed ID: 31030804 [TBL] [Abstract][Full Text] [Related]
34. Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab. Montal R; Oliva M; Taberna M; De Avila L; Rovira A; Cos M; Mañós M; Navarro V; Nogués J; Lozano A; Rodríguez L; Vilajosana E; Vázquez S; Mesia R Clin Transl Oncol; 2016 Nov; 18(11):1140-1146. PubMed ID: 26960559 [TBL] [Abstract][Full Text] [Related]
35. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659 [TBL] [Abstract][Full Text] [Related]
36. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696 [TBL] [Abstract][Full Text] [Related]
37. Patterns of recurrence after low-dose postoperative radiotherapy for head and neck squamous cell carcinoma. Makino W; Heianna J; Ishikawa K; Kusada T; Maemoto H; Ariga T; Matayoshi A; Nakasone T; Hirakawa H; Agena S; Yamashita Y; Maeda H; Murayama S J Egypt Natl Canc Inst; 2021 Dec; 33(1):40. PubMed ID: 34927227 [TBL] [Abstract][Full Text] [Related]
38. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Joshi BH; Kawakami K; Leland P; Puri RK Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640 [TBL] [Abstract][Full Text] [Related]
39. Prognostic and Predictive Relevance of Tumor-Infiltrating Lymphocytes in Squamous Cell Head-Neck Cancer Patients Treated with Radical Radiotherapy/Chemo-Radiotherapy. Koukourakis IM; Gkegka AG; Xanthopoulou E; Nanos C; Giatromanolaki A; Koukourakis MI Curr Oncol; 2022 Jun; 29(6):4274-4284. PubMed ID: 35735451 [TBL] [Abstract][Full Text] [Related]
40. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Tanvetyanon T; Padhya T; McCaffrey J; Kish JA; Deconti RC; Trotti A; Rao NG Head Neck; 2015 Jun; 37(6):840-5. PubMed ID: 24623654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]